Table 2.
Phase III studies with tiotropium Respimat® in children and adolescents with asthma
| Study name | Patients (asthma severity and age) | Treatment duration, weeks | Baseline therapy | N (treatment group) | Study drug |
|---|---|---|---|---|---|
| RubaTinA-asthma®41 | Moderate persistent 12–17-year-olds | 48 | At least ICS | 259 | Tiotropium |
| PensieTinA-asthma®42 | Severe persistent 12–17-year-olds | 12 | ICS +≥1 controller | 257 | Respimat 2.5 and 5 μg |
| CanoTinA-asthma®43 | Moderate persistent 6–11-year-olds | 48 | At least ICS | 270 | |
| VivaTinA-asthma®44 | Severe persistent 6–11-year-olds | 12 | At least ICS/+≥1 controller | 262 | |
| NinoTinA-asthma®45 | Persistent 1–5-year-olds | At least ICS | 67 |
Abbreviation: ICS, inhaled corticosteroids.